Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination

dc.contributor.authorGreenhouse, Bryan
dc.contributor.authorDaily, Jennifer
dc.contributor.authorGuinovart, Caterina
dc.contributor.authorGoncalves, Bronner
dc.contributor.authorBeeson, James G.
dc.contributor.authorBell, David
dc.contributor.authorChang, Michelle A.
dc.contributor.authorCohen, Justin M.
dc.contributor.authorDing, Xavier C.
dc.contributor.authorDomingo, Gonzalo
dc.contributor.authorEisele, Thomas P.
dc.contributor.authorLammie, Patrick J.
dc.contributor.authorMayor Aparicio, Alfredo Gabriel
dc.contributor.authorMerienne, Nicolas
dc.contributor.authorMonteiro, Wuelton Marcelo
dc.contributor.authorPainter, John
dc.contributor.authorRodríguez, Isabel
dc.contributor.authorWhite, Michael T.
dc.contributor.authorDrakeley, Chris
dc.contributor.authorMueller, Ivo
dc.contributor.authorMalaria Serology Convening
dc.date.accessioned2019-06-18T15:29:47Z
dc.date.available2019-06-18T15:29:47Z
dc.date.issued2019-06-07
dc.date.updated2019-06-14T09:57:39Z
dc.description.abstractMeasurement of malaria specific antibody responses represents a practical and informative method for malaria control programs to assess recent exposure to infection. Technical advances in recombinant antigen production, serological screening platforms, and analytical methods have enabled the identification of several target antigens for laboratory based and point-of-contact tests. Questions remain as to how these serological assays can best be integrated into malaria surveillance activities to inform programmatic decision-making. This report synthesizes discussions from a convening at Institut Pasteur in Paris in June 2017 aimed at defining practical and informative use cases for serology applications and highlights five programmatic uses for serological assays including: documenting the absence of transmission; stratification of transmission; measuring the effect of interventions; informing a decentralized immediate response; and testing and treating P. vivax hypnozoite carriers.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2572-4754
dc.identifier.urihttps://hdl.handle.net/2445/135362
dc.language.isoeng
dc.publisherBill and Melinda Gates Foundation
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.12688/gatesopenres.12897.1
dc.relation.ispartofGates Open Research, 2019, vol. 3 , num. 131
dc.relation.urihttp://dx.doi.org/10.12688/gatesopenres.12897.1
dc.rightscc by (c) Greenhouse et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationMalària
dc.subject.classificationSerodiagnòstic
dc.subject.otherMalaria
dc.subject.otherSerodiagnosis
dc.titlePriority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
GreenhouseB_Gates_Open_Res_2019.pdf
Mida:
311.88 KB
Format:
Adobe Portable Document Format